Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Top 5 Marijuana Stocks for 2019
With individual stock selection now more critical than ever, this report is designed to bring you some of our top ideas in the marijuana industry this year.
One of the companies highlighted in this report offers a life-changing therapy that reduces the number of seizures in children with two rare types of childhood-onset epilepsy. It has the potential for the stock to sky-rocket. You need to find out the name of this company before the rest of the market does.
P.S. Not many retail investors pay attention to the marijuana sector. Use this complimentary guide and get a head start on your path to profiting from the booming cannabis industry!
Menu

Supernus Pharm (SUPN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,950,489
  • Shares Outstanding, K 52,320
  • Annual Sales, $ 408,900 K
  • Annual Income, $ 110,990 K
  • 60-Month Beta 1.59
  • Price/Sales 4.65
  • Price/Cash Flow 14.82
  • Price/Book 4.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.44
  • Number of Estimates 5
  • High Estimate 0.52
  • Low Estimate 0.31
  • Prior Year 0.49
  • Growth Rate Est. (year over year) -10.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.90 +13.34%
on 03/28/19
39.15 -4.75%
on 04/08/19
+1.63 (+4.57%)
since 03/22/19
3-Month
32.90 +13.34%
on 03/28/19
43.05 -13.38%
on 02/27/19
+1.21 (+3.35%)
since 01/24/19
52-Week
30.05 +24.09%
on 12/24/18
61.25 -39.12%
on 06/29/18
-9.46 (-20.24%)
since 04/24/18

Most Recent Stories

More News
Global Lennox-Gastaut Syndrome Treatment Market 2019-2023 - Key Players are Eisai, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson Services, and Supernus Pharmaceuticals - ResearchAndMarkets.com

The "Global Lennox-Gastaut Syndrome Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

JNJ : 139.85 (-0.04%)
SUPN : 37.39 (+0.30%)
GSK : 39.94 (-0.70%)
Relatively Good Performance Detected in Shares of Dermira in the Pharmaceuticals Industry (DERM , SUPN , CTLT , RVNC , MDCO )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

DERM : 11.17 (-2.10%)
CTLT : 44.21 (-0.54%)
SUPN : 37.39 (+0.30%)
Relatively Good Performance Detected in Shares of Intra-Cellular T in the Pharmaceuticals Industry (ITCI , PRGO , SUPN , MNK , AGN )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

ITCI : 13.06 (+1.01%)
SUPN : 37.39 (+0.30%)
PRGO : 49.29 (-0.54%)
Supernus Pharmac has the Best Relative Performance in the Pharmaceuticals Industry (SUPN , MDCO , OMER , MNK , AERI )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

MDCO : 29.51 (+0.48%)
SUPN : 37.39 (+0.30%)
OMER : 18.83 (-0.63%)
Supernus Pharmac Rises 2.10% on Heavy Volume: Watch For Potential Pullback

Supernus Pharmac (NASDAQ:SUPN) traded in a range yesterday that spanned from a low of $36.11 to a high of $36.42. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high...

SUPN : 37.39 (+0.30%)
Supernus' ADHD Candidate Positive in 4th Phase III Study

Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.

RDY : 40.89 (unch)
SUPN : 37.39 (+0.30%)
SLGL : 7.01 (-3.44%)
MNK : 18.25 (-0.60%)
Supernus Announces Webcast of Investor Day on April 16, 2019

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it...

SUPN : 37.39 (+0.30%)
Supernus Hosts Conference Call to Present Topline Results of Final Phase III Study for SPN-812 in Adolescents with ADHD

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, on...

SUPN : 37.39 (+0.30%)
Supernus Pharmac Set to Possibly Rebound After Yesterday's Selloff of 3.37%

Supernus Pharmac (NASDAQ:SUPN) traded in a range yesterday that spanned from a low of $34.46 to a high of $34.98. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of...

SUPN : 37.39 (+0.30%)
Pacira Pharmaceu has the Best Relative Performance in the Pharmaceuticals Industry (PCRX , LCI , SUPN , ZGNX , OMER )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

LCI : 7.17 (-0.42%)
SUPN : 37.39 (+0.30%)
PCRX : 41.28 (+5.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade SUPN with:

Business Summary

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit...

See More

Key Turning Points

2nd Resistance Point 38.21
1st Resistance Point 37.74
Last Price 37.39
1st Support Level 36.39
2nd Support Level 35.51

See More

52-Week High 61.25
Fibonacci 61.8% 49.33
Fibonacci 50% 45.65
Fibonacci 38.2% 41.97
Last Price 37.39
52-Week Low 30.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar